Sonnetize Hyperliquid Strategies - Create $888 Million HYPE Treasury

Digital change - altcoin treasury

Sonnet BioTherapeutics, known for developing anti-cancer drugs based on the Fully Human Albumin Binding (FHAB) platform, is making a bold move. Sonnet has merged with Rorschach I, LLC, a startup backed by prominent firms such as Atlas Merchant Capital, Paradigm Operations, Pantera Capital, and Galaxy Digital. Instead of focusing solely on clinical trials like SON-1010, which is in phase 1/2a for ovarian cancer, Sonnet has

HSI, which will be ranked 13th in market capitalization after the merger, and will become a crypto treasury company, holding a large amount of HYPE tokens, the native currency of the Hyperliquid Layer-1 blockchain, according to Forbes. The

deal is a statement of vision and a change of strategy. Expanding the HYPE portfolio and developing treasury management strategies will be carried out by HSI under the leadership of Bob Diamond (Chairman, Co-Founder of Atlas Merchant Capital) and David Schamis (CEO, Co-Founder of Atlas).

Sonnet will continue to operate as a subsidiary, preserving the biotech assets and seeking research programs that can be licensed or sold. Conditional Value Rights (CVRs) will be granted to existing Sonnet shareholders, which will allow them to profit in the event that the biotech assets generate value in the future.

Hyperliquid and HYPE token - the new wave in blockchain

At the heart of the deal is the HYPE token, the native currency of Hyperliquid, a Layer-1 blockchain that specializes in perpetual derivatives trading. It has seen over $1.5 trillion in trading volume over the past year. The HyperBFT consensus algorithm and HyperLiquid’s two main components are HyperCore and HyperEVM. HyperCore supports spot and perpetual futures orders at 200,000 orders per second. HyperEVM is a general-purpose smart contract platform. Matt Huang, co-founder of Paradigm, said that while HYPE is attracting the attention of institutional investors, those in the United States still cannot use the token. Sonnet’s deal with Rorschach is seen as a way to strengthen the Hyperliquid ecosystem and expose HYPE to the U.S. market.

Hyperliquid’s growth potential is illustrated by the value of its 12.6 million HYPE tokens, which was worth $583 million at the time of the deal. HSI has strong financial resources and is managed by seasoned financial and cryptocurrency experts. It is also backed by leading investment funds such as Pantera and D1 Capital. This ensures that HSI can capitalize on the digital asset boom and position itself as one of the leaders in the crypto treasury space.

See more research on Hyperliquid!

New steps of reform

While the deal presents many opportunities, it also comes with some risks. First, the 12.6 million HYPE tokens worth $583 million can change rapidly, indicating that HYPE is a highly volatile digital asset. The value of HSI’s treasury could be severely affected if the cryptocurrency market takes a downturn.

Second, Sonnet’s shift from biotech to crypto treasury may make some conventional investors question the company’s strategy in the long run. Ultimately, the deal is subject to Sonnet shareholder approval and other requirements, and the transaction is expected to close in the second half of 2025.

But HSI presents an opportunity. HSI has the potential to become a model for public crypto treasury companies with the backing of top institutional investors and an experienced leadership team. Furthermore, Sonnet’s continued development of biotech assets as a subsidiary ensures that the company is not abandoning its core business, but instead looking to diversify its resources to maximize shareholder value.

Evaluation and Conclusion

Sonnet BioTherapeutics’ $888 million acquisition of Rorschach I LLC is a bold move to move the company from the biotech space into the new crypto space. Hyperliquid Strategies Inc. is backed by a large HYPE treasury and major companies like Paradigm and Galaxy Digital. is emerging as a leader in public crypto treasuries. HYPE’s growth and Sonnet’s diversification strategy offer hope for the future, despite headwinds ranging from market volatility to regulatory challenges.

Disclaimer: The information presented in this article is the author's personal opinion on the cryptocurrency field. It is not intended to be financial or investment advice. Any investment decision should be based on careful consideration of your personal portfolio and risk tolerance. The views expressed in the article do not represent the official position of the platform. We recommend that readers conduct their own research and consult with a professional before making any investment decisions.

Compiled and analyzed by HCCVenture

Join HCCVenture here: https://linktr.ee/holdcoincventure

See more latest information :